1Debernardi VW, Barletti C, Alessanddria C, et al. Efficacy of irbesartan, an angiorensin Ⅱ, in the treatment of portal hypertension [J] .Dig Dis Sci,2002,47 ,401 ～ 404. 被引量：1
2Schepke M, Werner E, Bicker E, et al. The angiotensin Ⅱ redeptor antagonist irbeasrtan for the treatments of portal hypertension: a placebo controlled,double - blind study[J]. Hepatology,2000,32:406. 被引量：1
3Timmernans PB, Wong PC, Chiu AT, et al. Angiotensin Ⅱ receptor antagonists[ J]. Pharmacol Rev, 1993,45: 205. 被引量：1
4Gasparo D, Hussain A, Alexander W, et al. Proposed update of angiotensin recepter nomenclature[ J]. Hypertension, 1995,25:924. 被引量：1
7Mclonaughey MM, Mclonnaughey JS, Ingenito AJ. Practical concidertion of the pharmacology of angiotension recepter blockers[J] .J Clin Pharmacol,1999,39:547 ～ 559. 被引量：1
9Jardine AG. Angiotensin Ⅱ and glomerulonephritis [J]. Am J Hypertens,1995,13:487. 被引量：1
10Ruiz OM, Gonez GD, Alcazar R, et al. Involvement of Angiotensin Ⅱ and endothelin in matrix protein prodruction and renal sclerosis[J]. Am J Hypertens, 2003,44:150. 被引量：1
